Association Between Subtypes of Anti Citrullinated Peptide Antibodies and Lung Damage in Rheumatoid Arthritis

NCT03832374 | Completed

• 1 other identifier: 15/E/27
• Study Type: observational
• Target: 77
• Locations: 1 country
• Sites: 1

Brief Summary

Rheumatoid arthritis is a genuine systemic disease associated with diffuse interstitial pneumopathy and bronchial disorders. According to the literature review, the prevalence of PID on thoracic CT scan is one-third of patients. Diffuse interstitial pneumopathy is responsible for a significant morbidity and mortality, is currently under-diagnosed and its treatment is poorly codified. The lung seems to have a central role in the genesis of rheumatoid arthritis. It also appears that some subtypes of anti citrullinated peptide antibodies are preferentially present in the lungs. The hypothesis behind our project is that one or more subtypes of anti citrullinated peptide antibodies with a preferential tropism for the lung would attack the parenchyma and pulmonary airways. Currently, there are no data on interstitial pneumopathy in black and Afro-Caribbean subjects with rheumatoid arthritis.

Conditions

Rheumatoid Arthritis

Outcome Measures

Primary Outcomes (1)

• Frequency of the positivity of the anti citrullinated peptide antibodies and subtype

  Presence of one or more subtypes of anti citrullinated peptide antibodies in the serum of patients with interstitial pneumopathy associated with rheumatoid arthritis who would be absent

  three years

Secondary Outcomes (1)

• Genetic analysis of the main mutations

  three years

Interventions

Descriptive OTHER

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with rheumatoid arthritis with diffuse insterstitial lung disease

You may qualify if:

• Patient with rheumatoid arthritis ACR/EULAR 2010
• Patient with a higher age or equal to 18
• Patient receiving social security
• Patient giving his free and informed written consent

You may not qualify if:

• Patient with overlap syndrome with another autoimmune disease
• Patients with known severe cardiopulmonary pathology
• Woman who is pregnant and breast feeding
• Patient with language difficulties or understanding

Sponsors & Collaborators

• University Hospital Center of Martinique: lead

Study Sites (1)

CHU Martinique

Fort-de-France, 97261, Martinique

Location

Biospecimen

Retention: SAMPLES WITH DNA

plasma, urine

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• BLETTERY Marie, MD

  CHU de Martinique

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 29, 2018
• First Posted: February 6, 2019
• Study Start: June 2, 2016
• Primary Completion: March 1, 2022
• Study Completion: March 1, 2022
• Last Updated: March 9, 2022

Record last verified: 2022-03

Locations

MA (1)